Skip to main content

Advertisement

SpringerLink
Log in

New developments in HBV molecular diagnostics and quantitative serology

  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

New standardized assays for the quantification of hepatitis B virus (HBV) DNA have yielded insights into the association of HBV DNA levels with the relative risk of developing liver disease. Quantification of HBV DNA has also played a role in the management of chronic hepatitis B by allowing criteria to be established for determining patient eligibility for antiviral therapy, monitoring response, and identifying the development of resistance. In addition to serum HBV DNA levels, the HBV genotype may influence disease progression and response to therapy. However, many of the studies that have included genotype assessment do not compare across the range of genotypes, and current management guidelines do not incorporate genotype determination. More recently, quantitative assays for intrahepatic HBV replicative intermediates, as well as hepatitis B e antigen and hepatitis B surface antigen, indicate that these factors may have promise in identifying patients likely to respond to treatment. Additional work is needed to standardize and validate these assays before they can be considered to be of true diagnostic value. A wide variety of research techniques are being used to investigate chronic hepatitis B. Further evaluation is needed to decide which will have the greatest clinical applicability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.

    Article  PubMed  CAS  Google Scholar 

  2. Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Res 2002;55:381–96.

    Article  PubMed  CAS  Google Scholar 

  3. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012–20.

    Article  PubMed  CAS  Google Scholar 

  4. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52–61.

    Article  PubMed  CAS  Google Scholar 

  5. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936–62.

    Article  PubMed  CAS  Google Scholar 

  6. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. Geneva, Switzerland, September 14–16, 2002. J Hepatol 2003;39 Suppl 1:S1–235.

    Google Scholar 

  7. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472–89.

    Article  PubMed  Google Scholar 

  8. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679–93.

    PubMed  CAS  Google Scholar 

  9. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63–71.

    Article  PubMed  CAS  Google Scholar 

  10. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267–80.

    PubMed  CAS  Google Scholar 

  11. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289–309.

    Article  PubMed  Google Scholar 

  12. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489–503.

    Article  PubMed  CAS  Google Scholar 

  13. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059–73.

    PubMed  CAS  Google Scholar 

  14. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67–74.

    PubMed  CAS  Google Scholar 

  15. Clarke B, Bloor S. Molecular genotyping of hepatitis B virus. J Clin Virol 2002;25 Suppl 3:S41–5.

    Article  PubMed  Google Scholar 

  16. Guettouche T, Hnatyszyn HJ. Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes. Antivir Ther 2005;10:593–604.

    PubMed  CAS  Google Scholar 

  17. Kao JH. Clinical relevance of hepatitis B viral genotypes: a case of deja vu? J Gastroenterol Hepatol 2002;17:113–5.

    Article  PubMed  Google Scholar 

  18. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002;76:5985–92.

    Article  PubMed  CAS  Google Scholar 

  19. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254–65.

    Article  PubMed  CAS  Google Scholar 

  20. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006;44:593–606.

    Article  PubMed  CAS  Google Scholar 

  21. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006;44:1094–7.

    Article  PubMed  CAS  Google Scholar 

  22. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51–68.

    Article  PubMed  CAS  Google Scholar 

  23. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006;44:694–702.

    Article  PubMed  CAS  Google Scholar 

  24. Singh M, Dicaire A, Wakil AE, Luscombe C, Sacks SL. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR. J Virol Methods 2004;118:159–67.

    Article  PubMed  CAS  Google Scholar 

  25. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750–8.

    Article  PubMed  CAS  Google Scholar 

  26. Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727–37.

    Article  PubMed  CAS  Google Scholar 

  27. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675–84.

    Article  PubMed  CAS  Google Scholar 

  28. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006;11:909–16.

    PubMed  CAS  Google Scholar 

  29. Hui CK, Bowden S, Jackson K, Au WY, Fong DY, Lie AK, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005;105:2616–7.

    Article  PubMed  CAS  Google Scholar 

  30. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890–7.

    Article  PubMed  CAS  Google Scholar 

  31. Yuen MF, Wong DK, Sum SS, Yuan HJ, Yuen JC, Chan AO, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005;100:1099–103.

    Article  PubMed  CAS  Google Scholar 

  32. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217–22.

    Article  PubMed  CAS  Google Scholar 

  33. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006;37:206–12.

    Article  PubMed  CAS  Google Scholar 

  34. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148–53.

    Article  PubMed  CAS  Google Scholar 

  35. Bernard F, Raymond G, Willems B, Villeneuve JP. Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997;4:265–72.

    Article  PubMed  CAS  Google Scholar 

  36. Heijtink RA, Kruining J, Honkoop P, Kuhns MC, Hop WC, Osterhaus AD, et al. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J Med Virol 1997;53:282–7.

    Article  PubMed  CAS  Google Scholar 

  37. Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556–62.

    Article  PubMed  Google Scholar 

  38. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744–8.

    PubMed  CAS  Google Scholar 

  39. Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004;127:756–63.

    Article  PubMed  Google Scholar 

  40. Fried M, Liaw Y-F, Luo K. Role of baseline and on-treatment quantitative HBeAg levels in predicting response to Peginterferon alfa-2a (40 kD) (Pegasys) monotherapy in a large, multinational trial of patients with chronic hepatitis B. Hepatology 2005;42:268A.

    Google Scholar 

  41. Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000;7:382–6.

    Article  PubMed  CAS  Google Scholar 

  42. Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. J Viral Hepat 2005;12:216–21.

    Article  PubMed  CAS  Google Scholar 

  43. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993;18:1306–12.

    Article  PubMed  CAS  Google Scholar 

  44. Shin JW, Park NH, Jung SW, Kim BC, Kwon SH, Park JS, et al. Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol 2006;12:6693–8.

    PubMed  CAS  Google Scholar 

  45. Wang CC, Liu CJ, Lai MY, Kao JH, Chen DS. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. Liver Int 2007;27:235–9.

    Article  PubMed  CAS  Google Scholar 

  46. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007;12:73–82.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC, Australia

    D. Scott Bowden & Alex J. Thompson

  2. Department of Microbiology, Monash University, Clayton, VIC, Australia

    D. Scott Bowden

  3. Department of Gastroenterology, St. Vincent’s Hospital, Fitzroy, VIC, Australia

    Alex J. Thompson

Authors
  1. D. Scott Bowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex J. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Scott Bowden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bowden, D.S., Thompson, A.J. New developments in HBV molecular diagnostics and quantitative serology. Hepatol Int 2 (Suppl 1), 3–11 (2008). https://doi.org/10.1007/s12072-008-9051-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-008-9051-8

Keywords

Search

Navigation